GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (OSTO:STABL) » Definitions » YoY EPS Growth

Stayble Therapeutics AB (OSTO:STABL) YoY EPS Growth : 47.62% (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Stayble Therapeutics AB YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Stayble Therapeutics AB's YoY EPS Growth for the quarter that ended in Sep. 2023 was 47.62%.

Stayble Therapeutics AB's Earnings per Share (Diluted) for the three months ended in Sep. 2023 was kr-0.22.


Stayble Therapeutics AB YoY EPS Growth Historical Data

The historical data trend for Stayble Therapeutics AB's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stayble Therapeutics AB YoY EPS Growth Chart

Stayble Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
YoY EPS Growth
Get a 7-Day Free Trial -117.72 -20.78 -108.78 51.01 -102.82

Stayble Therapeutics AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -96.26 - 50.91 44.68 47.62

Stayble Therapeutics AB YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Stayble Therapeutics AB's YoY EPS Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY EPS Growth (A: Dec. 2022 )
=(Earnings per Share (Diluted) (A: Dec. 2022 )-Earnings per Share (Diluted) (A: Dec. 2021 ))/ | Earnings per Share (Diluted) (A: Dec. 2021 ) |
=(-1.724--0.85)/ | -0.85 |
=-102.82 %

Stayble Therapeutics AB's YoY EPS Growth for the quarter that ended in Sep. 2023 is calculated as:

YoY EPS Growth (Q: Sep. 2023 )
=(Earnings per Share (Diluted) (Q: Sep. 2023 )-Earnings per Share (Diluted) (Q: Sep. 2022 )) / | Earnings per Share (Diluted) (Q: Sep. 2022 )) |
=(-0.22--0.42)/ | -0.42 |
=47.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stayble Therapeutics AB YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Stayble Therapeutics AB's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Stayble Therapeutics AB (OSTO:STABL) Business Description

Traded in Other Exchanges
Address
Medicinaregatan 8a, Gothenburg, SWE, SE-413 90
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.

Stayble Therapeutics AB (OSTO:STABL) Headlines

No Headlines